AbbVie 2013 Annual Report Download - page 113

Exhibit
Number Exhibit Description
10.8 *Luxembourg International Commercial Operations Agreement dated as of December 31,
2012 by and between Abbott Investments Luxembourg S.` ar.l. and AbbVie Investments S.` ar.l.
(incorporated by reference to Exhibit 10.7 of the Company’s Current Report on Form 8-K
filed on January 2, 2013).
10.9 First Amendment to Luxembourg International Commercial Operations Agreement effective
as of December 31, 2012 by and between Abbott Investments Luxembourg S.` ar.l. and AbbVie
Investments S.` ar.l.
10.10 *Information Technology Agreement dated as of December 31, 2012 by and between Abbott
Laboratories and AbbVie Inc. (incorporated by reference to Exhibit 10.8 of the Company’s
Current Report on Form 8-K filed on January 2, 2013).
10.11 *Transitional Trademark License Agreement dated as of December 31, 2012 by and between
Abbott Laboratories and AbbVie Inc. (incorporated by reference to Exhibit 10.9 of the
Company’s Current Report on Form 8-K filed on January 2, 2013).
10.12 *Form of Finished Goods Supply Agreements by and between Abbott Laboratories and
AbbVie Inc. (incorporated by reference to Exhibit 10.11 of Amendment No. 2 to the
Company’s Registration Statement on Form 10 filed on September 4, 2012).
10.13 *Form of Contract Manufacturing Agreements by and between Abbott Laboratories and
AbbVie Inc. (incorporated by reference to Exhibit 10.12 of Amendment No. 2 to the
Company’s Registration Statement on Form 10 filed on September 4, 2012).
10.14 *Form of Agreement Regarding Change in Control by and between AbbVie Inc. and its
named executive officers (incorporated by reference to Exhibit 10.13 of Amendment No. 5 to
the Company’s Registration Statement on Form 10 filed on November 16, 2012).**
10.15 *AbbVie 2013 Incentive Stock Program (incorporated by reference to Exhibit A to the
AbbVie Inc. Definitive Proxy Statement on Schedule 14A dated March 15, 2013).**
10.16 *AbbVie 2013 Management Incentive Plan (incorporated by reference to Exhibit 10.14 of the
Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.17 *AbbVie 2013 Performance Incentive Plan (incorporated by reference to Exhibit 10.15 of the
Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.18 *AbbVie Deferred Compensation Plan (incorporated by reference to Exhibit 10.16 of the
Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.19 *AbbVie Non-Employee Directors’ Fee Plan (incorporated by reference to Exhibit 10.17 of
the Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.20 *AbbVie Supplemental Pension Plan (incorporated by reference to Exhibit 10.18 of the
Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.21 *AbbVie Supplemental Savings Plan (incorporated by reference to Exhibit 10.19 of the
Company’s Annual Report on Form 10-K filed on March 15, 2013).**
10.22 *Purchase Agreement dated November 5, 2012 between AbbVie Inc., Abbott Laboratories, as
guarantor, and Morgan Stanley & Co. LLC, Barclays Capital Inc., J.P. Morgan Securities LLC,
and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to
Exhibit 10.21 of Amendment No. 6 to the Company’s Registration Statement on Form 10 filed
on November 30, 2012).
10.23 *Form of AbbVie Inc. Non-Employee Director Restricted Stock Unit Agreement
(incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2013).**
109